In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Finepoint Capital LP reported 18 stock positions worth $822.2 million . Its top holding was Qxo (QXO) at 49.4% of the portfolio, followed by Liberty Broadband-C (LBRDK, 18.7% ) and Revolution Medicines (RVMD, 4.0% ). Compared with Q2 2024, it opened 1 new position and added to 8. The biggest buy was a new position in Qxo (QXO).
Location BOSTON, MA
CIK 0001608126
Portfolio Value $822.2M (Q3 2024) Holdings 18 stocks · $822.2M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q2 2024 QXO Qxo Inc. 25,750,781 $406.1M New LBRDK Liberty Broadband-C 1,994,510 $154.2M No change RVMD Revolution Medicines Inc. 731,960 $33.2M Add +0.3% ARGX Argenx SE - ADR 54,428 $29.5M Add +0.7% ASND Ascendis Pharma A/S 190,072 $28.4M Add +0.4% TVTX Travere Therapeutics Inc. 1,782,267 $24.9M Add +0.3% SWTX Springworks Therapeutics Inc. 650,852 $20.9M Add +2.0% MLTX Moonlake Immunotherapeutics 388,835 $19.6M No change SRPT Sarepta Therapeutics Inc. 133,535 $16.7M Add +0.5% LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV 557,762 $16.1M Add +2.8% ARVN Arvinas Inc. 574,378 $14.1M No change ACAD Acadia Pharmaceuticals Inc. 905,384 $13.9M No change CYTK Cytokinetics Inc. 256,449 $13.5M No change RLAY Relay Therapeutics Inc. 1,626,146 $11.5M Add +1.3% PRTA Prothena Corp. PLC 433,471 $7.3M No change SLDB Solid Biosciences Inc. 961,251 $6.7M No change EYPT Eyepoint Inc. 707,404 $5.7M No change CLDI Calidi Biotherapeutics Inc. 12,500 $14K No change
Options reported separately and not counted above: SPY puts ($318.4M), IWM puts ($235.2M).
Other holdings (6): bonds, preferreds, convertibles and warrants · $152K (not counted above) Security Class Shares / Principal Value Change IVCPW Swiftmerge Acquisition -CW23 *W EXP 12/13/202 490,000 $39K No change CDAWF Compass Digital Acq -CW28 *W EXP 99/99/999 459,906 $28K No change MNYWW Moneyhero Ltd.-28 *W EXP 09/13/202 895,000 $27K No change GATEW Marblegate Acquisition -CW22 *W EXP 08/31/202 735,000 $25K No change LAKESHORE BIOPHARMA CO LTD *W EXP 03/15/202 489,999 $24K No change CLDWW Calidi Biotherapeutics -CW23 *W EXP 03/14/202 655,200 $9K No change
Total filed on the 13F, all lines: $822.3M.
Portfolio Sells Q2 2024 → Q3 2024 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q2 2024 % Of Portfolio Change To Portfolio ▲ None this quarter.
Portfolio Buys Q2 2024 → Q3 2024 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q2 2024 % Of Portfolio Change To Portfolio ▼ QXO Qxo Inc. New 49.39% +49.39 TVTX Travere Therapeutics Inc. Add +0.3% 3.03% −1.12 RLAY Relay Therapeutics Inc. Add +1.3% 1.40% −1.57 LKFT Lakefront Biotherapeutic-ADR Add +2.8% 1.95% −1.87 ARGX Argenx SE - ADR Add +0.7% 3.59% −3.02 ASND Ascendis Pharma A/S Add +0.4% 3.45% −3.89 SRPT Sarepta Therapeutics Inc. Add +0.5% 2.03% −3.94 RVMD Revolution Medicines Inc. Add +0.3% 4.04% −4.01 SWTX Springworks Therapeutics Inc. Add +2.0% 2.54% −4.30
Options Activity Q2 2024 → Q3 2024 Security Type Change vs Q2 2024 Underlying Shares Value ▼ SPY SS SPDR S&P 500 ETF Trust-US put New 555,000 $318.4M IWM iShares Russell 2000 ETF put New 1,065,000 $235.2M
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q2 2024 → Q3 2024 Security Class Change vs Q2 2024 Shares / Principal Value ▼ CVIIW Churchill Capital Vii -CW28 *W EXP 02/29/202 Sold out 548,000 $192Kbefore exit CNDAW Concord Acquisition A -CW28 *W EXP 99/99/999 Sold out 408,333 $45Kbefore exit
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 4 $460.8M QXO, RXO, ANNA, CLDI Q1 2026 4 $416.6M QXO, RXO, ANNA, CLDI Q4 2025 5 $532.7M QXO, RXO, SLDB, ANNA, CLDI Q3 2025 5 $542.8M QXO, RXO, SLDB, ANNA, CLDI Q2 2025 5 $504.1M QXO, LLYVK, SLDB, ANNA, CLDI Q1 2025 19 $592.5M QXO, LBRDK, SWTX, LLYVK, ASND Q4 2024 20 $866.7M QXO, LBRDK, LLYVK, ARGX, RVMD Q3 2024 18 $822.2M QXO, LBRDK, RVMD, ARGX, ASND Q2 2024 17 $351.8M LBRDK, RVMD, ASND, SWTX, ARGX Q1 2024 17 $376.0M LBRDK, SWTX, ASND, ARVN, RVMD